NO20065651L - Spesifikke bindingsmedlemmer - Google Patents

Spesifikke bindingsmedlemmer

Info

Publication number
NO20065651L
NO20065651L NO20065651A NO20065651A NO20065651L NO 20065651 L NO20065651 L NO 20065651L NO 20065651 A NO20065651 A NO 20065651A NO 20065651 A NO20065651 A NO 20065651A NO 20065651 L NO20065651 L NO 20065651L
Authority
NO
Norway
Prior art keywords
binding members
specific binding
binding
members
binding member
Prior art date
Application number
NO20065651A
Other languages
English (en)
Inventor
Linda Gillian Durrant
Tina Parsons
Original Assignee
Arana Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32526936&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065651(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arana Therapeutics Ltd filed Critical Arana Therapeutics Ltd
Publication of NO20065651L publication Critical patent/NO20065651L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer et isolert, spesifikt bindingsmedlem som er i stand til å binde et sialyltetraosylkarbohydrat og direkte indusere celledød uten behovet for immuneffektorceller. Et slikt bindingsmedlem kan være et antistoff eller en del derav. Også tilveiebrakt blir anvendelsen av slike bindingsmedlemmer i medisin og nukleinsyrer som koder for slike bindingsmedlemmer.
NO20065651A 2004-05-12 2006-12-07 Spesifikke bindingsmedlemmer NO20065651L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0410627.4A GB0410627D0 (en) 2004-05-12 2004-05-12 Specific binding members
PCT/GB2005/001805 WO2005108430A2 (en) 2004-05-12 2005-05-11 Monoclonal antibody sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent

Publications (1)

Publication Number Publication Date
NO20065651L true NO20065651L (no) 2007-02-06

Family

ID=32526936

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065651A NO20065651L (no) 2004-05-12 2006-12-07 Spesifikke bindingsmedlemmer

Country Status (17)

Country Link
US (2) US7915387B2 (no)
EP (3) EP2392598A1 (no)
JP (2) JP4944016B2 (no)
KR (1) KR101213282B1 (no)
CN (1) CN1961004B (no)
AU (2) AU2005240837B2 (no)
BR (1) BRPI0510950A (no)
CA (1) CA2563516C (no)
ES (1) ES2400571T3 (no)
GB (1) GB0410627D0 (no)
HK (1) HK1101696A1 (no)
IL (1) IL178791A (no)
MX (1) MXPA06012955A (no)
NO (1) NO20065651L (no)
NZ (3) NZ550738A (no)
WO (1) WO2005108430A2 (no)
ZA (1) ZA200609365B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
MX2011009704A (es) 2009-03-16 2011-09-28 Cephalon Australia Pty Ltd Anticuerpos humanizados con actividad anti-tumor.
US8932588B2 (en) 2009-11-05 2015-01-13 Teva Pharmaceuticals Australia Pty. Ltd. Treatment of cancer involving mutated KRAS or BRAF genes
EP2663579B1 (en) 2011-01-14 2017-04-26 The Regents of the University of California Therapeutic antibodies against ror-1 protein and methods for use of same
GB201319374D0 (en) 2013-11-01 2013-12-18 Univ Nottingham Glycans as functional cancer targets abd antibodies thereto
ES2924393T3 (es) * 2014-04-16 2022-10-06 Inst Nat Sante Rech Med Anticuerpos para la prevención o el tratamiento de episodios hemorrágicos

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
AU7757581A (en) 1980-11-19 1982-05-27 United Energy Technologies Inc. Enhanced surface tubing
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS5811808A (ja) 1981-07-16 1983-01-22 Niles Parts Co Ltd 方位検出表示回路
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3464682D1 (en) 1983-05-09 1987-08-13 Gen Electric Co Plc Cathode ray tube display device
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CZ282603B6 (cs) * 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanizované a chimerické monoklonální protilátky
US5795965A (en) * 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
DE4118120A1 (de) * 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
DE69529649T2 (de) * 1994-03-17 2003-12-18 Merck Patent Gmbh Anti-egfr einkettige fvs und anti-egfr antikoerper
JPH09173063A (ja) 1995-12-26 1997-07-08 Cosmo Sogo Kenkyusho:Kk 抗ヒトリポタンパク質（ａ）モノクローナル抗体可変領域のＤＮＡ塩基配列およびアミノ酸配列
US6451995B1 (en) * 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
WO1999009055A2 (en) 1997-08-18 1999-02-25 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
CA2447139C (en) 2001-05-11 2013-11-19 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
BRPI0510950A (pt) 2007-11-20
EP1745077B1 (en) 2012-11-28
AU2005240837A1 (en) 2005-11-17
KR20070085116A (ko) 2007-08-27
HK1101696A1 (en) 2007-10-26
MXPA06012955A (es) 2007-04-25
US20110212113A1 (en) 2011-09-01
ZA200609365B (en) 2008-05-28
WO2005108430A2 (en) 2005-11-17
AU2011200487B2 (en) 2012-11-01
JP4944016B2 (ja) 2012-05-30
GB0410627D0 (en) 2004-06-16
US20080118509A1 (en) 2008-05-22
CN1961004B (zh) 2012-11-07
ES2400571T3 (es) 2013-04-10
WO2005108430A3 (en) 2006-04-27
US7915387B2 (en) 2011-03-29
CN1961004A (zh) 2007-05-09
CA2563516A1 (en) 2005-11-17
EP2392598A1 (en) 2011-12-07
NZ593171A (en) 2012-08-31
KR101213282B1 (ko) 2012-12-17
JP2008502324A (ja) 2008-01-31
CA2563516C (en) 2013-10-01
NZ550738A (en) 2011-03-31
AU2011200487A1 (en) 2011-02-24
NZ589214A (en) 2012-02-24
US8343490B2 (en) 2013-01-01
IL178791A0 (en) 2007-03-08
AU2005240837B2 (en) 2010-11-11
IL178791A (en) 2012-07-31
JP2012105654A (ja) 2012-06-07
EP1745077A2 (en) 2007-01-24
EP2397500A1 (en) 2011-12-21

Similar Documents

Publication Publication Date Title
NO20083266L (no) Humane anti-IL-23-antistoffer, sammensetninger, fremgangsmater og anvendelser
NO20065651L (no) Spesifikke bindingsmedlemmer
NO20065366L (no) Antistoffer og molekyler som er avledet fra disse som binder til STEAP-1-proteiner
WO2006073748A3 (en) Antibodies against antigen presenting cells and uses thereof
NO20065084L (no) Interferon-alfa polypeptider og konjugater
ATE353955T1 (de) Durch zelloberflächenmoleküle induzierte makrophagenaktivierung
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
NO20052363L (no) Interferon-alfa polypeptider og konjugater
NO20075103L (no) Antistoffer og relaterte molekyler som bindes til 161P2F10B proteiner
NO20062015L (no) Anti-NIK-antistoffer og anvendelser derav
NO20052714L (no) Fremgangsmater og materialer for behandling av inflammatoriske tilstander
WO2007037910A3 (en) Specific removal of activated immune cells
WO2020120569A3 (en) Modified carrier proteins for o-linked glycosylation
NO882818L (no) Gjenstand som er i stand til aa gjenvinne sine opprinnelige dimensjoner, og anvendelse av denne.
ATE555124T1 (de) Nukleinsäuren und entsprechende proteine 58p1d12 zum nachweis von krebs
Halavaty et al. Type III effector NleH2 from Escherichia coli O157: H7 str. Sakai features an atypical protein kinase domain
Altuntaş Kur'an Perspekti̇fi̇nden Dünyanin Değeri̇
WO2006105168A3 (en) Enhancing immune responses with bacterial exotoxins
Gomase et al. In-Silico Approach for Prediction of Vaccine Potential Antigenic Peptides from 23-kDa Transmembrane Antigen Protein of Schistosoma haematobium
CY1112424T1 (el) Πυρηνικο οξυ και αντιστοιχη πρωτεϊνη με τιτλο 238ρ1β2 χρησιμα στην αγωγη και ανιχνευση του καρκινου
NO20075592L (no) Antistoffer og beslektede molekyler som bindes til PSCA Proteiner
郑兰英 Cultural Differences and Translation
Stone Fingertip Windows.
Voss Protein chips
WO2006076383A3 (en) Composition and method for inducing a protective vaccine response

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TEVA PHARMACEUTICALS AUSTRALIA PTY LTD, AU

FC2A Withdrawal, rejection or dismissal of laid open patent application